top of page
Browse by category
Search
ADA and Lilly collaborate on new resources for obesity care
The American Diabetes Association (ADA) has announced a new suite of resources to support improved care for those living with obesity....
Zepbound (tirzepatide) is the first and only FDA approved prescription medicine for moderate-to-severe OSA in adults with obesity
The FDA has approved Eli Lilly and Company’s Zepbound (tirzepatide) as the first and only prescription medicine for adults with...
Laekna and Eli Lilly to develop ActRIIA antibody for muscle-preserving weight loss in obesity
Laekna Therapeutics has entered a clinical collaboration with Eli Lilly to accelerate the development of LAE102, a novel Activin Receptor...
Lilly and UK government announce £279 million collaboration to tackle population health challenges including obesity
Eli Lilly and Company has announced a strategic collaboration with the UK’s Department of Health and Social Care (DHSC), Department for...
Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity
Eli Lilly and Company has announced Zepbound (tirzepatide) 2.5mg and 5mg single-dose vials are available for self-pay for patients with...
WHO issues warning on falsified medicines as Lilly warns patients about counterfeit and compounded medicines
The World Health Organization (WHO) has issued a medical product alert on falsified semaglutides, the type of medicines that are used for...
Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesity
Eli Lilly and Company has announced positive topline results from the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide...
Lilly's Zepbound (tirzepatide) achieved total mean weight loss of 26.0% from baseline to 88 weeks
Detailed results from SURMOUNT-4 have shown Zepbound (tirzepatide) injection achieved superior mean percent change in body weight...
Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide
Novo Nordisk is planning a study that will see CagriSema, a new investigational medicine developed by Novo that combines Cagrilintide and...
Once-daily oral nonpeptide GLP-1-RA achieved up to 14.7% mean weight reduction at 36 weeks
Phase 2 data for orforglipron (12 mg, 24 mg, 36 mg or 45 mg), a nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, has...
Browse by tag
bottom of page